Skip to main content

Immune signatures predict prognosis in localized cancer.

Publication ,  Journal Article
Hsu, DS; Kim, MK; Balakumaran, BS; Acharya, CR; Anders, CK; Clay, T; Lyerly, HK; Drake, CG; Morse, MA; Febbo, PG
Published in: Cancer Invest
August 2010

The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (T(H1)-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n = 79), breast cancer (n = 132), lung cancer (n = 84), glioblastoma multiforme (n = 120), and lymphoma (n = 127) were analyzed. Among adenocarcinomas, the T(H1)-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the T(H1)-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p = .04, hazard ratio [HR] = 0.42) and in prostate cancer patients (p = .03, HR = 0.36) but not in lung cancer patients (p = 0.45, HR = 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the T(H1)-mediated adaptive immunity genes (p = .01, HR = 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p = 0.05, HR = 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.

Duke Scholars

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

August 2010

Volume

28

Issue

7

Start / End Page

765 / 773

Location

England

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Inflammation
  • Immune Tolerance
  • Humans
  • Gene Expression Profiling
  • Gene Expression
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hsu, D. S., Kim, M. K., Balakumaran, B. S., Acharya, C. R., Anders, C. K., Clay, T., … Febbo, P. G. (2010). Immune signatures predict prognosis in localized cancer. Cancer Invest, 28(7), 765–773. https://doi.org/10.3109/07357900903095755
Hsu, David S., Mickey K. Kim, Bala S. Balakumaran, Chaitanya R. Acharya, Carey K. Anders, Tim Clay, H Kim Lyerly, Charles G. Drake, Michael A. Morse, and Phillip G. Febbo. “Immune signatures predict prognosis in localized cancer.Cancer Invest 28, no. 7 (August 2010): 765–73. https://doi.org/10.3109/07357900903095755.
Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, et al. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug;28(7):765–73.
Hsu, David S., et al. “Immune signatures predict prognosis in localized cancer.Cancer Invest, vol. 28, no. 7, Aug. 2010, pp. 765–73. Pubmed, doi:10.3109/07357900903095755.
Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug;28(7):765–773.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

August 2010

Volume

28

Issue

7

Start / End Page

765 / 773

Location

England

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Inflammation
  • Immune Tolerance
  • Humans
  • Gene Expression Profiling
  • Gene Expression